4-甲基-2-苯基-1,3-噁唑-5-羧酸 | 91137-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基-2-苯基-1,3-噁唑-5-羧酸
• 英文名称: 4-methyl-2-phenyl-1,3-oxazole-5-carboxylic acid
• 英文别名: 4-methyl-2-phenyloxazole-5-carboxylic acid；4-methyl-2-phenyl-oxazole-5-carboxylic acid；4-Methyl-2-phenyl-oxazol-5-carbonsaeure；4-Methyl-2-phenyl-5-oxazolcarboxylsaeure；2-Phenyl-4-methyl-4-oxazolcarbonsaeure
• CAS: 91137-55-2
• 化学式: C₁₁H₉NO₃
• mdl: MFCD01566859
• 分子量: 203.197
• InChiKey: HRFYZRHGBICKAG-UHFFFAOYSA-N

物化性质

• 熔点：
  237 °C (decomp)
• 沸点：
  400.1±37.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-甲基-2-苯基-1,3-噁唑-5-羧酸 、 (2-amino-benzylamino)-acetic acid ethyl ester 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Towards Gram-negative antivirulence drugs: New inhibitors of HldE kinase

  摘要：

  Gram-negative bacteria lacking heptoses in their lipopolysaccharide (LPS) display attenuated virulence and increased sensitivity to human serum and to some antibiotics. Thus inhibition of bacterial heptose synthesis represents an attractive target for the development of new antibacterial agents. HldE is a bifunctional enzyme involved in the synthesis of bacterial heptoses. Development of a biochemical assay suitable for high-throughput screening allowed the discovery of inhibitors 1 and 2 of HldE kinase. Study of the structure-activity relationship of this series of inhibitors led to highly potent compounds. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.021
• 作为产物：
  描述：

  ethyl 2-benzoyloxy-3-oxobutanoate 在 氢氧化钾 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 反应 51.0h， 生成 4-甲基-2-苯基-1,3-噁唑-5-羧酸
  参考文献：
  名称：

  Cornwall, Philip; Dell, Colin P.; Knight, David W., Journal of the Chemical Society. Perkin transactions I, 1991, # 10, p. 2417 - 2428

  摘要：

  DOI：

文献信息

• Aerobic copper-catalyzed decarboxylative thiolation
  作者：Minghao Li、Jessica M. Hoover

  DOI：10.1039/c6cc04486g

  日期：——

  Copper-catalyzed decarboxylative thiolation using molecular oxygen as the sole oxidant was developed. A variety of aromatic carboxylic acids including 2-nitrobenzoic acids, pentafluorobenzoic acid and several heteroaromatic carboxylic acids undergo efficient...

  开发了使用分子氧作为唯一氧化剂的铜催化脱羧硫醇化反应。包括2-硝基苯甲酸，五氟苯甲酸和几种杂芳族羧酸在内的各种芳族羧酸均经过有效的...
• Diacylglycerol acyltransferase inhibitors
  申请人：Bolin Robert David

  公开号：US20070123504A1

  公开（公告）日：2007-05-31

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
  申请人：Escaich Sonia

  公开号：US20100022541A1

  公开（公告）日：2010-01-28

  The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR 1 , C1-C10 alkyl-NR 1 R 1 , alkoxy, hydroxy, thioalkyl, aryl, heterocycle, halogen, nitro, cyano, CO 2 R 1 , NR 1 R 1 , NR 1 C(O)R 1 , C(O)NR 1 R 1 , NR 1 C(S)R 1 , C(S)NR 1 R 1 , SO 2 NR 1 R 1 , SO 2 R 1 , NR 1 SO 2 R 1 , NR 1 C(O)NR 1 R 1 , NR 1 C(O)OR 1 , NR 1 C(S)NR 1 R 1 , NR 1 C(S)OR 1 , R 1 C═NOR 1 , C(O)R 1 , aryloxy, thioaryl, alkenyl, alkynyl R1 identical or different is H or C1-C10 alkyl B 1 , B 2 , B 3 identical or not represent C, N, O, S to form a five-membered aromatic ring wherein from one to three carbon atoms are replaced by a heteroatom selected from S, O, N optionally substituted by one or several identical or different R such as defined above B 4 is C or N Y is H, C1-C10 alkyl, alkoxy, thio-alkyl, optionally substituted by one or several identical or different R such as defined above W is C, O or N, substituted or not by one or several C1-C10 alkyl radicals D is an heterocycle optionally substituted by one or several identical or different R such as defined above.

  本发明涉及具有抑制庚糖合成特性的新化合物，其具有式(I)或其药学上可接受的盐或前药，其中A为芳基或杂环，任选地被一个或多个相同或不同的R取代，如H、C1-C10烷基、C1-C10烷基-OR1、C1-C10烷基-NR1R1、烷氧基、羟基、硫代烷基、芳基、杂环、卤素、硝基、氰基、CO2R1、NR1R1、NR1C(O)R1、C(O)NR1R1、NR1C(S)R1、C(S)NR1R1、SO2NR1R1、SO2R1、NR1SO2R1、NR1C(O)NR1R1、NR1C(O)OR1、NR1C(S)NR1R1、NR1C(S)OR1、R1C═NOR1、C(O)R1、芳氧基、硫代芳基、烯基、炔基，R1相同或不同为H或C1-C10烷基；B1、B2、B3相同或不同，代表C、N、O、S以形成五元芳香环，其中一到三个碳原子被选自S、O、N的杂原子替换，任选地被一个或多个相同或不同的如上定义的R取代；B4为C或N；Y为H、C1-C10烷基、烷氧基、硫代烷基，任选地被一个或多个相同或不同的如上定义的R取代；W为C、O或N，被或不被一个或多个C1-C10烷基基团取代；D为任选地被一个或多个相同或不同的如上定义的R取代的杂环。
• [EN] ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ACYLPIPÉRAZINE À TITRE DE BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012020567A1

  公开（公告）日：2012-02-16

  The present invention relates to acyl piperazine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及酰基哌嗪衍生物，具有阻断电压门控钠通道（如TTX-S通道）活性的特性，可用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的疾病中使用这些化合物和组合物。
• Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors
  作者：Xue Xu、Liming Deng、Lu Nie、Yueming Chen、Yanzhi Liu、Rongrong Xie、Zheng Li

  DOI：10.1016/j.bmcl.2019.01.005

  日期：2019.2

  The xanthine oxidase (XO) plays an important role in producing uric acid, and therefore XO inhibitors are considered as one of the promising therapies for hyperuricemia and gout. We have previously reported a series of XO inhibitors with pyrazole scaffold to extend the chemical space of current XO inhibitors. Herein, we describe further structural optimization to explore the optimal heterocycle by

  黄嘌呤氧化酶（XO）在产生尿酸中起着重要作用，因此XO抑制剂被认为是高尿酸血症和痛风的有前途的疗法之一。我们先前已经报道了一系列带有吡唑骨架的XO抑制剂，以扩展当前XO抑制剂的化学空间。在这里，我们描述了进一步的结构优化，以通过用该领域未开发的5个杂环骨架取代非布索坦的噻唑环来探索最佳杂环。所有这些努力导致了化合物8的鉴定，该化合物是一种具有新型2-苯基噻唑-4-羧酸支架的有效XO抑制剂（IC50 = 48.6 nM）。此外，铅化合物8在草酸钾-次黄嘌呤诱导的高尿酸血症小鼠中表现出低尿酸作用。